HNB
CRDL

Huntington National Bank’s Cardiol Therapeutics CRDL Stock Holding History

Huntington National Bank’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-241
Closed -$477 – 4177
2024
Q3 		$477 Buy
+241
New +$500 ﹤0.01% 2490

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Atria Investments Charlotte, North Carolina $8.94B AUM 20.84% 1-Year Est. Return

Huntington National Bank's CRDL Position: Q4 2024 in Review

Huntington National Bank sold out of Cardiol Therapeutics (CRDL) in Q4 2024, closing a stake of 241 shares — an estimated $477 sold.

Huntington National Bank first reported a position in CRDL in Q3 2024 and held it in 1 quarter. The position peaked at $477 in Q3 2024. 43 funds tracked by Wall St. Rank hold CRDL as of Q4 2024.

  • Huntington National Bank reported no remaining Cardiol Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Huntington National Bank sold 241 Cardiol Therapeutics shares in Q4 2024, an estimated $477.
  • Huntington National Bank first reported a position in Cardiol Therapeutics in Q3 2024 and held it in 1 quarter.
  • Huntington National Bank's Cardiol Therapeutics position peaked at $477 in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2024.

Based on Huntington National Bank's 13F filing for Q4 2024, filed 12 Feb 2025.